Double-Blind Study of Miglitol in Japanese With type2 Diabetes

NCT ID: NCT00380822

Last Updated: 2006-09-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the efficacy and safety of miglitol in Japanese patients with type 2 diabetes that is insufficiently controlled diet alone.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

alpa-glucosidase inhibitor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

miglitol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type2 diabetic patient on Dietary Therapy
* Criteria for postprandial plasma glucose and HbA1c are met

Exclusion Criteria

* Type1 diabetes
* Patients treated with antidiabetic drugs or Insulin
Minimum Eligible Age

20 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanwa Kagaku Kenkyusho Co., Ltd.

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical study Group, Clinical Development Dept.

Role: STUDY_DIRECTOR

Sanwa Kagaku Kenkyusho Co., Ltd.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aichi, , Japan

Site Status

Chiba, , Japan

Site Status

Fukuoka, , Japan

Site Status

Gunma, , Japan

Site Status

Hiroshima, , Japan

Site Status

Hyōgo, , Japan

Site Status

Ibaraki, , Japan

Site Status

Ishikawa, , Japan

Site Status

Kumamoto, , Japan

Site Status

Kyoto, , Japan

Site Status

Mie, , Japan

Site Status

Miyagi, , Japan

Site Status

Nagasaki, , Japan

Site Status

Niigata, , Japan

Site Status

Numakunai, , Japan

Site Status

Okayama, , Japan

Site Status

Osaka, , Japan

Site Status

Ōita, , Japan

Site Status

Saga, , Japan

Site Status

Saitama, , Japan

Site Status

Shiga, , Japan

Site Status

Shimane, , Japan

Site Status

Shizuoka, , Japan

Site Status

Tokyo, , Japan

Site Status

Toyama, , Japan

Site Status

Yamagata, , Japan

Site Status

Yamaguchi, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MG1001

Identifier Type: -

Identifier Source: org_study_id